Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Gregory

Emergency Medicine Charleston, SC Medical Doctor

NPI 1073556452 CMS profile 48205

2060 Charlie Hall Blvd Ste A, Charleston, SC 29414

Open in the dashboard

General payments

$39,746

328 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Gregory of Charleston, SC is reported in the CMS Open Payments database as having received $39,746 across 328 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,076 34
2024 General $31,964 120
2023 General $1,330 64
2022 General $798 16
2021 General $1,056 20
2020 General $2,492 39
2019 General $1,029 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Gregory
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Timothy Gregory were reported at $1,076. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Timothy Gregory Emergency Medicine median Middle half National median
2019 $1,029 $51 $18–$128 $163
2020 $2,492 $29 $16–$99 $114
2021 $1,056 $40 $18–$124 $132
2022 $798 $49 $20–$134 $149
2023 $1,330 $51 $22–$142 $160
2024 $31,964 $52 $22–$150 $164
2025 $1,076 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ConvaTec Inc. $31,130 77 payments
  2. Organogenesis Inc. $3,533 79 payments
  3. Next Science LLC $1,769 19 payments
  4. Smith+Nephew, Inc. $1,166 94 payments
  5. KCI USA, Inc $684 11 payments
  6. Acera Surgical, Inc. $344 7 payments
  7. Integra LifeSciences Corporation $339 16 payments
  8. Musculoskeletal Transplant Foundation Inc. $201 1 payment
  9. Bioventus LLC $136 2 payments
  10. Kerecis Limited $72 3 payments
  11. Other $371 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Debt forgiveness $29,872 60 payments
  2. Food and Beverage $7,755 265 payments
  3. Honoraria $1,500 1 payment
  4. Travel and Lodging $619 2 payments
Products named General payments · program years 2019–2025
  1. INNOVAMATRIX AC $31,130 77 payments
  2. BlastX $1,510 2 payments
  3. Puraply $1,223 29 payments
  4. Affinity $499 10 payments
  5. ACTIV.A.C. $483 8 payments
  6. COLLAGENASE SANTYL $365 48 payments
  7. Apligraf $287 8 payments
  8. GRAFIX PL $270 20 payments
  9. Santyl $260 16 payments
  10. Xperience $259 17 payments
  11. Other $4,990 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

91

Median for Emergency Medicine: 88

Drug cost

$1,341

Median for Emergency Medicine: $590

Branded share of claims

13.2%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 61 $643
Gentamicin Sulfate Generic 18 $584
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $115

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$2,474,727

Of which drugs: $2,301,623

Medicare patients

97

Average age 76

Services billed

6,208

58 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 52%
Chronic kidney disease 45%
Ischemic heart disease 38%
Atrial fibrillation 36%
Heart failure 33%
COPD 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Cygnus dual, per square centimeter Q4282 Office 23 2,629 $1,517,678
Novachor, per square centimeter Q4194 Office 27 788 $618,156
Puraply xt, per square centimeter Q4197 Office 14 1,316 $63,909

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

328 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record